BioSpace News Archive

Business

Boehringer, Ochre Bio Team in Potential $1B Deal to Develop Regenerative Liver Drugs

Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.

April 22, 2024
·
2 min read
·
Nick Paul Taylor
Biotech Bay

BMS Taps Cellares in $380M CAR T Cell Therapy Manufacturing Agreement

Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.

April 22, 2024
·
2 min read
·
Tyler Patchen
Policy

Biosimilar Sales Up as Insurers Begin Dropping Humira Coverage

Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.

April 22, 2024
·
4 min read
·
Mollie Barnes
Policy

CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices

Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.

April 22, 2024
·
2 min read
·
Tristan Manalac
AbbVie Tops Doctor Ranking of Immunology Companies, Handily Beating Pfizer and J&J

Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.

April 22, 2024
·
2 min read
·
Tristan Manalac
Drug Development

AbbVie, NeuroDerm Heat Up Levodopa Competition with New Data at AAN24

As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.

April 22, 2024
·
2 min read
·
Tristan Manalac
Business

Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.

April 22, 2024
·
2 min read
·
Tristan Manalac
Business

Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign

Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil to supply its mRNA COVID-19 vaccine as an integral part of Brazil’s 2024 national vaccination campaign against COVID-19.

April 22, 2024
·
4 min read
Drug Development

Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update

Salubris Biotherapeutics, Inc. today announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs.

April 22, 2024
·
6 min read
Deals

Bruker to Acquire the NanoString Business in an Asset Deal

Bruker Corporation announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis.

April 22, 2024
·
7 min read